Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PABPC1 | P11940 | 1/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | GFER | P55789 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9886534 | 1.00 | PABPC1 (0.32) | PABPC1HSP90AA1GAAPKMMAPK1 | |
| SCHEMBL9886538 | 1.00 | PABPC1 (0.32) | PABPC1HSP90AA1GAAPKMMAPK1 | |
| SCHEMBL9911034 | 1.00 | PABPC1 (0.32) | PABPC1HSP90AA1GAAPKMMAPK1 | |
| SCHEMBL18143023 | 1.00 | PABPC1 (0.32) | PABPC1HSP90AA1GAAPKMMAPK1 | |
| SCHEMBL22980335 | 0.81 | ERBB2 (0.35) | PKMMAPK1TDP1 | |
| SCHEMBL22980337 | 0.81 | ERBB2 (0.35) | PKMMAPK1TDP1 | |
| SCHEMBL9886530 | 0.80 | ERBB2 (0.34) | — | |
| SCHEMBL9911033 | 0.80 | ERBB2 (0.34) | — | |
| SCHEMBL9886539 | 0.80 | — | — | |
| SCHEMBL9105522 | 0.80 | ERBB2 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142969-A1 | Process for the Preparation of 2-Methoxymethyl-1,4-Benzenediamine, Its Derivatives Thereof and the Salts Thereof | WELLA OPERATIONS US, LLC | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142969-A1 | Process for the Preparation of 2-Methoxymethyl-1,4-Benzenediamine, Its Derivatives Thereof and the Salts Thereof | KRT18, VIM, KDM4B | PABPC1 1824/4885HSP90AA1 1427/4885GAA 3264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.